CONTEXT: Presentation of a retrospective study in migraine epidemiology in Southern Israel at the 7th Congress of the European Academy of Neurology (EAN). Findings showed extreme variability in the prevalence of diagnosed patients with migraine across the region, predominantly based on socio-economic factors.
IMPACT: Low
READ TIME: 1 min
Quality Level Mean [1 – 10]: 6
1. “A 2020 Teva-sponsored research project, Beyond Migraine: The Real You, surveyed over 7,500 people living with the disease in 10 European countries.”
2. “AMSTERDAM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today presented new epidemiology data on migraine from the State of Israel which indicate that socio-economic factors may contribute to underdiagnosis of migraine across society1.”
3. “A retrospective study of migraine epidemiology in Southern Israel, supported by Teva and presented at the virtual 7th Congress of the European Academy of Neurology (EAN), found extreme variability in the prevalence of diagnosed patients with migraine across the geographic area studied.”
4. ““We were pleased to support these research efforts, which throw into sharp relief the social inequality which is clearly prevalent in migraine,” said Dr Joshua M. Cohen, Senior Director and Global Therapeutic Area Lead, Migraine and Headache, Teva.”
5. ““Our commitment as Teva is to support improvements in migraine holistically, working with the neurology community and allied professionals to advance not only effective therapies, but better diagnosis, information and conditions for all those who live with this debilitating disease.”